Technology partnerships
Hovione is keen to consider partnerships with third
parties to study novel technologies that have a fit with Hovione technical
activity and business strategy. Hovione will devote time and resources
to apply a third party's technology to relevant projects, products or
processes, in order to jointly study a novel technology and assess its
application and benefits within the scope of the API and pharmaceutical
development.
Hovione´s policy on Partnerships for the study of novel
technologies includes:
| 1.
|
Hovione will not commit to
using a novel technology before performing a joint study to assess
and quantify its benefits and fit with its technical strategy. |
|
|
| 2. |
Hovione will pay royalties
for using a technology based on direct process saving achieved through
the use of the technology. |
|
|
| 3. |
Hovione will not make up front
payments for the study or testing of a technology, including the evaluation
of equipment. |
|
|
| 4. |
The study and assessment of
a novel application will include studies at a Hovione site and will
be carried out by both Hovione and technology holder's personnel.
|
Hovione is interested in studying and testing novel technology applicable
in any area related to API development and formulation. We are currently
active in:
| •
|
New methods for the industrial
production of APIs – in batch or continuous process |
|
|
| • |
"Green Chemistry"
applicable to the production of APIs |
|
|
| • |
Analytical testing methods
|
|
|
| • |
Particle design |
|
|
| • |
Nanotechnology |
|
|
| • |
Pulmonary inhalation |
A reciprocal secrecy agreement will be put in place.
In the last 12 months, Hovione provided the API or formulated
product for more than 40 different NDA drug product projects.
For further information please contact Ms Paula Costa, Innovation
and Product Development at or
+ 351 21 982 9136.
|
About Hovione 
Press room
Press releases and articles
